dsm-firmenich PHARMA SOLUTIONS
We’re passionate about pioneering the next frontier in medicine – one that’s fueled by cannabinoid research and development. As an end-to-end partner to our customers, we offer a unique innovation platform powered by expert services. Designed to enhance the odds of therapeutic breakthroughs and streamline development pathways in the cannabinoid space, we’re enabling our customers to unlock new treatment possibilities and convenience for patients worldwide.
Discover our high-quality cannabidiol (CBD) pharma API portfolio, as well as the technical, clinical and regulatory expertise you need to navigate the ever-evolving cannabinoid market and expand into new geographies with confidence.
dsm-firmenich and Brains Bioceutical bring proven capabilities to simplify complex cannabinoid research and development; helping to reduce risks across the entire drug development pathway and support your path to success.
Download our NEW brochure to unlock the potential of customized cannabinoid-based pharmaceuticals. Learn more about how dsm-firmenich and Brains Bioceutical together as your end-to-end partner can help you enter the market with confidence.
dsm-firmenich has developed CBtru®, a premium formulated CBD drug intermediate and patented solution, that presents several exciting opportunities for patients, healthcare professionals, and manufacturers of pharmaceutical products.
Learn how to navigate the complexities of cannabinoid-based innovation more effectively. Download our whitepaper to uncover the key considerations at every stage of the drug pathway – from choosing the right cannabinoid API, all the way to fine-tuning patient experience, convenience and compliance.
We currently live in the most exciting time in human history for cannabis research, thanks in large part to eroding prohibition policies around the world and the emergence of the international medical cannabis industry. Demand for cannabinoid-based pharmaceutical products is greater now than ever before, and with more countries modernizing their cannabis policies to permit the research and development of such products, the future is very bright for the cannabinoid pharmaceutical sector. This panel was dedicated to discussing the future of cannabinoid-based pharmaceutical research and product development, joined by Athanasia Kanli, Global Market Development Manager, dsm-firmenich.
Get in touch with a dsm-firmenich Pharma specialist or find contacts around the world to suit your needs.
At dsm-firmenich, we love to connect with other humans.
Follow us on any of the channels below.
